Hamburger Menu icon

Focused on Hematology,
Dedicated to Patients

Innovation

There are millions of patients whose lives are affected by
and suffer from hematologic diseases. From rare blood
disorders to widespread, chronic disorders, there are a
host of diseases that require creative, new approaches
and a willingness to pioneer new fields of biology.

learn more about our science

Impact

We are committed to turning scientific discoveries into
useful therapies that will have a meaningful impact on
the lives of patients and their families. We are pursuing
the development of treatments that will potentially save
lives, alleviate suffering and enable patients to lead
vibrant lives.

learn more about our pipeline

Inspiration

Our team of talented scientists and industry veterans draws 
motivation and meaning from the work we do and the patients 
we hope to help. We are also inspired by a shared drive, tireless 
dedication and desire to make a difference that brings us together 
as colleagues.

learn more about our team

In The News

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg…


read more

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track…


read more

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and…


read more